April 7, 2017 — The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were…Original Article
FDA Approves Two Hepatitis C Drugs – Sovaldi and Harvoni – for Pediatric Patients
